Taiyen Biotech Co., Ltd. (TPE:1737)
Taiwan · Delayed Price · Currency is TWD 31.40
-0.05 (-0.16%)
Feb 11, 2026, 1:30 PM CST
Taiyen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 3,273 | 3,238 | 3,409 | 3,614 | 4,096 | 3,130 | |
Revenue Growth (YoY) | 1.67% | -5.01% | -5.67% | -11.77% | 30.84% | 7.70% |
Cost of Revenue | 1,948 | 1,917 | 2,151 | 2,337 | 2,722 | 1,823 |
Gross Profit | 1,326 | 1,321 | 1,257 | 1,277 | 1,373 | 1,308 |
Selling, General & Admin | 850.04 | 835.39 | 801.98 | 770.92 | 786.46 | 770.29 |
Research & Development | 56.07 | 54.71 | 60.5 | 60.64 | 57.6 | 73.98 |
Operating Expenses | 942.97 | 974.38 | 936.04 | 831.56 | 844.06 | 844.27 |
Operating Income | 382.89 | 346.53 | 321.44 | 445.05 | 529.18 | 463.32 |
Interest Expense | -5.72 | -6.34 | -3.35 | -4.52 | -5.94 | -3.61 |
Interest & Investment Income | 30.75 | 37.93 | 35.93 | 17.88 | 10.66 | 15.19 |
Earnings From Equity Investments | - | - | - | - | - | -0.55 |
Currency Exchange Gain (Loss) | -6.46 | 38.54 | -5.67 | 58.69 | -20.59 | -16.64 |
Other Non Operating Income (Expenses) | 40.74 | 11 | -21.26 | 20.65 | 1.93 | 4.92 |
EBT Excluding Unusual Items | 442.21 | 427.66 | 327.1 | 537.74 | 515.23 | 462.62 |
Gain (Loss) on Sale of Investments | 5.01 | 12.85 | 7.43 | -0.36 | -0.54 | 3.17 |
Gain (Loss) on Sale of Assets | -1.05 | -1.04 | -1.28 | -1.28 | -1.24 | -1.76 |
Other Unusual Items | -23.22 | -6.44 | -4.13 | -5.52 | -3.54 | - |
Pretax Income | 422.94 | 433.03 | 329.12 | 530.59 | 509.92 | 464.04 |
Income Tax Expense | 96.34 | 115.58 | 111.82 | 103.07 | 97.76 | 89.45 |
Earnings From Continuing Operations | 326.61 | 317.45 | 217.3 | 427.52 | 412.16 | 374.59 |
Minority Interest in Earnings | 6.83 | 54.07 | 83.09 | -0.81 | -18.94 | -9.5 |
Net Income | 333.44 | 371.52 | 300.39 | 426.7 | 393.23 | 365.09 |
Net Income to Common | 333.44 | 371.52 | 300.39 | 426.7 | 393.23 | 365.09 |
Net Income Growth | 12.03% | 23.68% | -29.60% | 8.51% | 7.71% | 5.67% |
Shares Outstanding (Basic) | 200 | 200 | 200 | 200 | 200 | 200 |
Shares Outstanding (Diluted) | 201 | 201 | 200 | 201 | 201 | 201 |
Shares Change (YoY) | 0.08% | 0.06% | -0.08% | 0.05% | - | 0.02% |
EPS (Basic) | 1.67 | 1.86 | 1.50 | 2.13 | 1.97 | 1.83 |
EPS (Diluted) | 1.66 | 1.85 | 1.50 | 2.13 | 1.96 | 1.82 |
EPS Growth | 12.18% | 23.33% | -29.58% | 8.67% | 7.69% | 5.81% |
Free Cash Flow | 277.82 | 352.51 | 112.89 | 334.58 | 211.29 | 74.59 |
Free Cash Flow Per Share | 1.39 | 1.76 | 0.56 | 1.67 | 1.05 | 0.37 |
Dividend Per Share | 1.300 | 1.300 | 1.200 | 1.500 | 1.500 | 1.350 |
Dividend Growth | 8.33% | 8.33% | -20.00% | - | 11.11% | -10.00% |
Gross Margin | 40.50% | 40.79% | 36.89% | 35.33% | 33.53% | 41.77% |
Operating Margin | 11.70% | 10.70% | 9.43% | 12.32% | 12.92% | 14.80% |
Profit Margin | 10.19% | 11.47% | 8.81% | 11.81% | 9.60% | 11.66% |
Free Cash Flow Margin | 8.49% | 10.89% | 3.31% | 9.26% | 5.16% | 2.38% |
EBITDA | 613.12 | 553.56 | 508.88 | 628.74 | 707.81 | 640.44 |
EBITDA Margin | 18.73% | 17.09% | 14.93% | 17.40% | 17.28% | 20.46% |
D&A For EBITDA | 230.23 | 207.03 | 187.44 | 183.69 | 178.64 | 177.12 |
EBIT | 382.89 | 346.53 | 321.44 | 445.05 | 529.18 | 463.32 |
EBIT Margin | 11.70% | 10.70% | 9.43% | 12.32% | 12.92% | 14.80% |
Effective Tax Rate | 22.78% | 26.69% | 33.98% | 19.43% | 19.17% | 19.28% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.